EP1381365A1 - Pyrrolidine sulfonamides - Google Patents

Pyrrolidine sulfonamides

Info

Publication number
EP1381365A1
EP1381365A1 EP02757820A EP02757820A EP1381365A1 EP 1381365 A1 EP1381365 A1 EP 1381365A1 EP 02757820 A EP02757820 A EP 02757820A EP 02757820 A EP02757820 A EP 02757820A EP 1381365 A1 EP1381365 A1 EP 1381365A1
Authority
EP
European Patent Office
Prior art keywords
methyl
piperazin
butyl
yloxy
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02757820A
Other languages
German (de)
French (fr)
Other versions
EP1381365A4 (en
Inventor
Dashyant Dhanak
Steven D. Knight
Jian Jin
Ralph A. Rivero
Anthony Sapienza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1381365A1 publication Critical patent/EP1381365A1/en
Publication of EP1381365A4 publication Critical patent/EP1381365A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • cardiovascular homeostasis The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation. Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this status quo can result in cardiohemodynamic dysfunction with pathological consequences.
  • the principal mammalian vasoactive factors that comprise this neurohumoral axis namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with specific G-protein coupled receptors (GPCR).
  • GPCR G-protein coupled receptors
  • this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:
  • osmoregulation effects which include the modulation of transepithelial ion (Na + , Cl " ) transport. Although a diuretic effect has been described, such an effect is postulated to be secondary to direct renovascular effects (elevated GFR)
  • Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, fibrosis (e.g. pulmonary fibrosis), restenosis, atherosclerosis, dyslipidemia, asthma, (Hay DWP, Luttmann MA, Douglas SA: 2000, Br J Pharmacol: 131; 10-12) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-H and GPR14 are both expressed within the mammalian CNS (Ames et. al.
  • this invention provides for pyrrolidine sulfonamides and pharmaceutical compositions containing them.
  • this invention provides for the use of pyrrolidine sulfonamides as antagonists of urotensin II, and as inhibitors of urotensin II.
  • this invention provides for the use of pyrrolidine sulfonamides for treating conditions associated with urotensin II imbalance.
  • this invention provides for the use of pyrrolidine sulfonamides for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory diseases, fibrosis (e.g.
  • pulmonary fibrosis sepsis
  • atherosclerosis dyslipidemia
  • addiction schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, pain, neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and genitourinary diseases.
  • the urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, A-II receptor antagonists, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ - adrenoceptor and j -adrenoceptor antagonists.
  • ACE angiotensin converting enzyme
  • the present invention provides for compounds of Formula (I):
  • R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, or benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, C ⁇ _3 alkyl, Cj.3 alkoxy, or methylenedioxy groups;
  • R is C _6 alkyl, benzyl, or (CH2) n -C(0)NH2; wherein the benzyl may be unsubstituted or substituted by one or two C . alkyl, halogen, C j .g alkoxy, or methylenedioxy groups;
  • X j and X2 are independently hydrogen, halogen, C1.3 alkyl, Cj_3 alkoxy, nitro, CF3, or CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
  • alkyl includes all straight chain and branched isomers.
  • Representative examples thereof include methyl, ethyl, n-propyl, w ⁇ -propyl, n-butyl, sec- butyl, iso-batyl, t-butyl, /z-pentyl and n-hexyl.
  • halogen' and halo' include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their diastereoisomers are contemplated to be within the scope of the present invention.
  • R2 is benzothiopheneyl
  • X j is hydrogen, 3-Bromo, or 3-Chloro; and X2 is hydrogen or 5-Chloro.
  • Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2- ⁇ 4-[3-bromo-4-((S)-pyrrolidin-3-yloxy)- benzenesulfonyl]-piperazin-l-yl ⁇ -ethylcarbamoyl)-3-methyl-butyl]-amide
  • Benzo[b]thiophene-2-carboxylic acid [(S)-3-methyl-l-(2- ⁇ 4-[4-(piperidin-4-yloxy) ⁇ benzenesulfonyl]-piperazin-l-yl ⁇ -ethylcarbamoyl)-butyl]-amide
  • resin-bound amine 3 was prepared by reductive animation of 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde (DMHB resin) piperazinyl- ethylamine HCl salt 2 which was prepared from l-(2-aminoethyl)piperazine (1). Reactions of resin-bound amine 3 with various amino acids, followed by removal of the protecting group, resulted in the corresponding resin-bound amines 4. Amines 4 were then reacted with various acids to afford the corresponding resin-bound amides 5. Resin-bound amides 5 were subsequently treated with potassium carbonate and thiophenol to give secondary amines 6.
  • DMHB resin 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde
  • Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration.
  • Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, , with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa- ' > butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.
  • a topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).
  • the daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid.
  • the daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
  • sulphonamide analogs may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.
  • the urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ -adrenoceptor and oq- adrenoceptor antagonists.
  • agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective ⁇ -adrenoceptor and oq- adrenoceptor antagonists.
  • ACE angiotensin converting enzyme
  • Radioligand binding HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [1251] h-U-II (200 Ci/mmol "1 in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgC12). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester. 1 5 ⁇ l beled U-II binding was quantitated by gamma counting. Nonspecific binding was defined by 125j u_ ⁇ binding in the presence of 100 nM of unlabeled human U-II. Analysis of the data was performed by nonlinear least square fitting.
  • Ca 2+ -mobilization A microtitre plate based Ca 2+ -mobilization FLIPR assay (Molecular Devices,
  • HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 uCi myo- H] inositol per ml of inositol free Dulbecco's modified Eagel's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 min at 37°C.
  • DPBS Dulbecco's phosphate-buffered saline
  • the experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to l ⁇ M ) in the absence and presence of three different concentrations (0.3, 1 and 10 uM) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation.
  • the supematants were neutralized with lOOul of IM Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate.
  • the resulting mixture was stirred at 0 °C for 1 h and warmed to rt and stirred at rt for 16 h.
  • the mixture was diluted with 1.5 L of CH 2 C1 2 and poured into 1 L of 1 M NaHC0 3 aqueous solution. After stirring for 15 min, the organic layer was separated and washed with 1 L of 1 M NaHC0 3 aqueous solution. The resulting organic layer was dried over K2CO3 and concentrated in vacuo. The residue was dissolved into 400 mL of 1,4-dioxane. The solution was concentrated in vacuo to remove the remaining triethylamine.
  • the above resin (7.914 mmol) was treated with 175 mL of 20% piperidine in anhydrous l-methyl-2-pyrrolidinone solution. After the mixture was shaken at rt for 15 min, the solution was drained and another 175 mL of 20% piperidine in anhydrous 1- methyl-2-pyrrolidinone solution was added. The mixture was shaken at rt for another 15 min. The solution was drained and the resin was washed with l-methyl-2-pyrrolidinone (3 x 175 mL), CH 2 Cl 2 /MeOH (1:1, 3 x 175 mL) and CH 2 C1 2 (3 x 175 mL).
  • the mixture was then allowed to warm to 0 °C over 1 h and shaken at rt for 19 h.
  • the resin was washed with tetrahydrofuran (3 x 10 mL), CH 2 Cl 2 /methanol (1:1, 10 x 10 mL).
  • the resulting resin was dried in vacuum oven at 35 °C for 24 h.
  • the dry resin was treated with
  • EXAMPLE 11 Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • Step 1 Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender.
  • Step 2 Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
  • Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • Step 4 The wet granules are then dried in an oven at 140°F (60°C) until dry.
  • Step 5 The dry granules are lubricated with ingredient No. 5.
  • Step 6 The lubricated granules are compressed on a suitable tablet press.
  • a compound of Formula I (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Abstract

The present invention relates to pyrrolidine sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists.

Description

PYRROLIDINE SULFONAMIDES
FIELD OF THE INVENTION
The present invention relates to pyrrolidine sulfonamides, pharmaceutical compositions containing them and their use as urotensin II antagonists
BACKGROUND OF THE INVENTION
The integrated control of cardiovascular homeostasis is achieved through a combination of both direct neuronal control and systemic neurohormonal activation. Although the resultant release of both contractile and relaxant factors is normally under stringent regulation, an aberration in this status quo can result in cardiohemodynamic dysfunction with pathological consequences.
The principal mammalian vasoactive factors that comprise this neurohumoral axis, namely angiotensin-II, endothelin-1, norepinephrine, all function via an interaction with specific G-protein coupled receptors (GPCR). Urotensin-II, represents a novel member of this neurohumoral axis.
In the fish, this peptide has significant hemodynamic and endocrine actions in diverse end-organ systems and tissues:
• smooth muscle contraction both vascular and non- vascular in origin including smooth muscle preparations from the gastrointestinal tract and genitourinary tract. Both pressor and depressor activity has been described upon systemic administration of exogenous peptide
• osmoregulation: effects which include the modulation of transepithelial ion (Na+, Cl") transport. Although a diuretic effect has been described, such an effect is postulated to be secondary to direct renovascular effects (elevated GFR)
• metabolism: urotensin-II influences prolactin secretion and exhibits a lipolytic effect in fish (activating triacylglycerol lipase resulting in the mobilization of non-esterified free fatty acids)
(Pearson, et. al. Proc. Natl. Acad. Sci. (U.S.A.) 1980, 77, 5021; Conlon, et. al. J. Exp. Zool. 1996, 275, 226.) In studies with human Urotensin-II it was found that it:
• was an extremely potent and efficacious vasoconstrictor
• exhibited sustained contractile activity that was extremely resistant to wash out
• had detrimental effects on cardiac performance (myocardial contractility) Human Urotensin-II was assessed for contractile activity in the rat-isolated aorta and was shown to be the most potent contractile agonist identified to date. Based on the in vitro pharmacology and in vivo hemodynamic profile of human Urotensin-II it plays a pathological role in cardiovascular diseases characterized by excessive or abnormal vasoconstriction and myocardial dysfunction. (Ames et. al. Nature 1999, 401, 282; Douglas & Ohlstein (2001). Trends Cardiovasc. Med., 10: in press). Compounds that antagonize the Urotensin-II receptor may be useful in the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, fibrosis (e.g. pulmonary fibrosis), restenosis, atherosclerosis, dyslipidemia, asthma, (Hay DWP, Luttmann MA, Douglas SA: 2000, Br J Pharmacol: 131; 10-12) neurogenic inflammation and metabolic vasculopathies all of which are characterized by abnormal vasoconstriction and/or myocardial dysfunction. Since U-H and GPR14 are both expressed within the mammalian CNS (Ames et. al. Nature 1999, 401 , 282), they also may be useful in the treatment of addiction, schizophrenia, cognitive disorders/Alzheimers disease, (Gartlon J. Psychopharmacology (Berl) 2001 Jun ; 155(4) :426- 33), impulsivity, anxiety, stress, depression, pain, migraine, and neuromuscular function. Functional U-II receptors are expressed in rhabdomyosarcomas cell lines and therefore may have oncological indications. Urotensin may also be implicated in various metabolic diseases such as diabetes (Ames et. al. Nature 1999, 401, 282, Nothacker et al., Nature Cell Biology 1: 383-385, 1999) and in various gastrointestinal disorders, bone, cartilage, and joint disorders (e.g. arthritis and osteoporosis); and genito-urinary disorders. Therefore, these compounds may be useful for the prevention (treatment) of gastric reflux, gastric motility and ulcers, arthritis, osteoporosis and urinary incontinence.
SUMMARY OF THE INVENTION In one aspect this invention provides for pyrrolidine sulfonamides and pharmaceutical compositions containing them.
In a second aspect, this invention provides for the use of pyrrolidine sulfonamides as antagonists of urotensin II, and as inhibitors of urotensin II.
In another aspect, this invention provides for the use of pyrrolidine sulfonamides for treating conditions associated with urotensin II imbalance. In yet another aspect, this invention provides for the use of pyrrolidine sulfonamides for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation, migraine, metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory diseases, fibrosis (e.g. pulmonary fibrosis), sepsis, atherosclerosis, dyslipidemia, addiction, schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, pain, neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and genitourinary diseases.
The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, A-II receptor antagonists, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β- adrenoceptor and j-adrenoceptor antagonists.
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides for compounds of Formula (I):
Formula (I) wherein:
R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, or benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, Cι_3 alkyl, Cj.3 alkoxy, or methylenedioxy groups;
R is C _6 alkyl, benzyl, or (CH2)n-C(0)NH2; wherein the benzyl may be unsubstituted or substituted by one or two C . alkyl, halogen, Cj.g alkoxy, or methylenedioxy groups;
Xj and X2 are independently hydrogen, halogen, C1.3 alkyl, Cj_3 alkoxy, nitro, CF3, or CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
When used herein, the term "alkyl" includes all straight chain and branched isomers.
Representative examples thereof include methyl, ethyl, n-propyl, wø-propyl, n-butyl, sec- butyl, iso-batyl, t-butyl, /z-pentyl and n-hexyl.
When used herein, the terms halogen' and halo' include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively. The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active form. All of these compounds and their diastereoisomers are contemplated to be within the scope of the present invention.
Preferrably:
m is 1 or 2; R| is isobutyl;
R2 is benzothiopheneyl;
Xj is hydrogen, 3-Bromo, or 3-Chloro; and X2 is hydrogen or 5-Chloro.
Preferred Compounds are:
Benzo[fe]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-chloro-4-(piperidin-4-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-bromo-4-(piperidin-4-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-chloro-4-((S)-pyrrolidin-3-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-bromo-4-((S)-pyrrolidin-3-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide Benzo[b]thiophene-2-carboxylic acid [(S)-3-methyl-l-(2-{4-[4-(piperidin-4-yloxy)~ benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-butyl]-amide
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3,5-dichloro-4-(piperidin-4-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide
Compounds of Formula (I) may be prepared as set forth in scheme 1.
Scheme 1
e, f
Conditions: a) tert-butylchlorodiphenyl silane, triethylamine, CH2C12, 50 °C; b) 2- nitrobenzenesulfonyl chloride, 0 °C - rt; c) 4 M HCl in 1,4-dioxane, it; d) 2,6-dimethoxy-4- polystyrenebenzyloxy-benzaldehyde (DMHB resin), Na(OAc)3BH, diisopropylethylamine, 1% acetic acid in l-methyl-2-pyrrolidinone, rt; e) Fmoc-HNCH(Rι)COOH, 1,3- diisopropylcarbodiimide, l-hydroxy-7-azabenzotriazole, l-methyl-2-pyrrolidinone, rt; f) 20% piperidine in l-methyl-2-pyrrolidinone, it; g) R2COOH, 1,3-diisopropylcarbodiimide, l-hydroxy-7-azabenzotriazole, l-methyl-2-pyrrolidinone, rt; h) K2C03, PhSH, l-methyl-2- pyrrolidinone, rt; i) (Xι)(X2)-4-hydroxy-benzenesulfonyl chloride, 1,2-dichloroethane, 1- methyl-2-pyrrolidinone, rt; j) potassium trimethylsilanolate, tetrahydrofuran, rt; k) R2OH, diisopropyl azodicarboxylate, PPh3, tetrahydrofuran, - 78 °C - rt; 1) 50% trifluoroacetic acid in 1,2-dichloroethane, it.
As shown in scheme 1, resin-bound amine 3 was prepared by reductive animation of 2,6-dimethoxy-4-polystyrenebenzyloxy-benzaldehyde (DMHB resin) piperazinyl- ethylamine HCl salt 2 which was prepared from l-(2-aminoethyl)piperazine (1). Reactions of resin-bound amine 3 with various amino acids, followed by removal of the protecting group, resulted in the corresponding resin-bound amines 4. Amines 4 were then reacted with various acids to afford the corresponding resin-bound amides 5. Resin-bound amides 5 were subsequently treated with potassium carbonate and thiophenol to give secondary amines 6. Sulfonylation of resin-bound amines 6 with various hydroxy-benzenesulfonyl chlorides, followed by treatment with potassium trimethylsilanolate, produced resin-bound phenols 7. Phenols 7 were then reacted with various alcohols in the presence of triphenylphosphine and diisopropyl azodicarboxylate to give the corresponding resin-bound phenol ethers which were treated with 50% trifluoroacetic acid in 1,2-dichloroethane to afford targeted compounds 8. With appropriate manipulation, including the use of alternative nitrogen protecting group(s), the synthesis of the remaining compounds of Formula (I) was accomplished by methods analogous to those above and to those described in the Experimental section.
In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
Compounds of Formula (I) and their pharmaceutically acceptable salts may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, transdermally, rectally, via inhalation or via buccal administration. Compounds of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, agar, pectin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil, or sesame oil.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane. A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, , with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa- ' > butter or other low melting vegetable waxes or fats or their synthetic analogues.
Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to themselves a single dose. Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 1.0% of a compound of Formula (I).
The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.
These sulphonamide analogs may be used for the treatment of congestive heart failure, stroke, ischemic heart disease (angina, myocardial ischemia), cardiac arrhythmia, hypertension (essential and pulmonary), COPD, restenosis, asthma, neurogenic inflammation and metabolic vasculopathies, addiction, schizophrenia, impulsivity, anxiety, stress, depression, neuromuscular function, and diabetes.
The urotensin antagonist may be administered alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, vasopeptidase inhibitors, diuretics, digoxin, and dual non-selective β-adrenoceptor and oq- adrenoceptor antagonists.
No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the following tests: ' '• '
Radioligand binding: HEK-293 cell membranes containing stable cloned human and rat GPR-14 (20 ug/assay) were incubated with 200 pM [1251] h-U-II (200 Ci/mmol"1 in the presence of increasing concentrations of test compounds in DMSO (0.1 nM to 10 uM), in a final incubation volume of 200 ul (20 mM Tris-HCl, 5 mM MgC12). Incubation was done for 30 minutes at room temperature followed by filtration GF/B filters with Brandel cell harvester. 1 5\ l beled U-II binding was quantitated by gamma counting. Nonspecific binding was defined by 125j u_π binding in the presence of 100 nM of unlabeled human U-II. Analysis of the data was performed by nonlinear least square fitting.
Ca2+-mobilization: A microtitre plate based Ca2+-mobilization FLIPR assay (Molecular Devices,
Sunnyvale, CA) was used for the functional identification of the ligand activating HEK-293 cells expressing (stable) recombinant GPR-14. The day following transfection, cells were plated in a poly-D-lysine coated 96 well black/clear plates. After 18-24 hours the media was aspirated and Fluo 3AM-loaded cells were exposed to various concentrations (10 nM to 30 uM) of test compounds followed by h-U-II. After initiation of the assay, fluorescence was read every second for one minute and then every 3 seconds for the following one minute. The inhibitory concentration at 50% (IC50)was calculated for various test compounds.
Inositol phosphates assays:
HEK-293-GPR14 cells in T150 flask were prelabeled overnight with 1 uCi myo- H] inositol per ml of inositol free Dulbecco's modified Eagel's medium. After labeling, the cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and then incubated in DPBS containing 10 mM LiCl for 10 min at 37°C. The experiment was initiated by the addition of increasing concentrations of h-U-II (1 pM to lμM ) in the absence and presence of three different concentrations (0.3, 1 and 10 uM) of test compounds and the incubation continued for an additional 5 min at 37°C after which the reaction was terminated by the addition of 10% (final concentration) trichloroacetic acid and centrifugation. The supematants were neutralized with lOOul of IM Trizma base and the inositol phosphates were separated on AG 1-X8 columns (0.8 ml packed, 100-200 mesh) in formate phase. Inositol monophosphate was eluted with 8 ml of 200 mM ammonium formate. Combined inositol di and tris phosphate was eluted with 4ml of IM ammonium formate/ 0.1 M formic acid. Eluted fractions were counted in beta scintillation counter. Based on shift from the control curve KB was calculated.
Activity for the compounds of this invention range from (radioligand binding assay): Ki = 5 nM - 10000 nM (example 5 Ki = 1400 nM)
The following Examples are illustrative but not limiting embodiments of the present invention.
Example 1 Preparation of Benzorblthiophene-2-carboxylic acid r(S)-3-methyI-l-(2-{4-r4-(piperidin-4- yloxy)-benzenesulfonyl1-piperazin-l-yl}-ethylcarbamoyl)-butyl1-amide
a) 2-[4-(2-Nitro-benzenesulfonyl)-piperazin-l-yl]-ethylamine HCl salt
To a solution of 100 mL (760.8 mmol) of l-(2-aminoethyl)piperazine in 636 mL (4.56 mol) of triethylamine and 800 mL of anhydrous CH2C12 at it under argon was added 198 mL (760.8 mmol) of tert-butylchlorodiphenyl silane. The mixture was refluxed at 50 °C for 2.5 h. The mixture was then cooled to 0 °C. 168.6 g (760.8 mmol) of 2- nitrobenzenesulfonyl chloride was added to the mixture in 3 portions. The resulting mixture was stirred at 0 °C for 1 h and warmed to rt and stirred at rt for 16 h. The mixture was diluted with 1.5 L of CH2C12 and poured into 1 L of 1 M NaHC03 aqueous solution. After stirring for 15 min, the organic layer was separated and washed with 1 L of 1 M NaHC03 aqueous solution. The resulting organic layer was dried over K2CO3 and concentrated in vacuo. The residue was dissolved into 400 mL of 1,4-dioxane. The solution was concentrated in vacuo to remove the remaining triethylamine.
The above residue was dissolved in 1 L of anhydrous 1,4-dioxane and was diluted with 2 L of anhydrous ether. The resulting mixture was treated with 800 mL of 4 M HCl solution in 1,4-dioxane under argon. The mixture was vigorously stirred at it under argon for 1 h. The resulting suspension was filtered. The precipitation was washed 5 times with 500 mL portions of anhydrous ether. The resulting solid was dried in vacuum oven for 24 h to yield 2-[4-(2-nitro-benzenesulfonyl)-piperazin-l-yl]-ethylamine HCl salt as a white solid
(340 g, 80% pure): MS (ESI) 315 [M+H]+ (which was contaminated with ~ 20% of the dinosyl-protected amine HCl salt: MS (ESI) 500 [M+H]+. It is not necessary to purify the crude product, however, the pure amine HCl salt example la could be obtained via recrystallization of the criide product in MeOH).
b) 4-Hydroxybenzenesulfonyl chloride To chlorosulfonic acid (248 mL, 3.37 ol) cooled to -3 °C was added dropwise a solution of phenol (70 g, 0J44 mol) in 250 mL of anhydrous methylene chloride over a period of 1 hour under argon gas. The mixture was warmed to rt over 1 h and was stirred at rt for 1.5 h. The mixture was poured over ice, stirred for 30 min, and was extracted with methylene chloride (4 x 2 L). The resulting organic layer was dried over MgS04 and concentrated in vacuo to yield 4-hydroxybenzenesulfonyl chloride as a sticky brown solid
(41.49g, 29%): H NMR (400 MHz, d5-DMSO) δ 7.29-7.38 (d, 2 H), 6.58-6.69 (d, 2 H).
c) Benzo[fe]thiophene-2-carboxylic acid [(S)-3-methyl-l-(2-{4-[4-(piperidin-4-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-butyl]-amide To a mixture of 20.20 g (29.08 mmol, 1.44 mmol/g) of 2,6-dimethoxy-4- polystyrenebenzyloxy-benzaldehyde (DMHB resin) in 439.4 mL of 1% acetic acid in anhydrous l-methyl-2-pyrrolidinone was added 27.42 g (70.8 mmol) of 2-[4-(2-nitro- benzenesulfonyl)-piperazin-l-yl]-ethylamine HCl salt and 25.33 mL (145.4 mmol) of diisopropylethyl amine, followed by addition of 30.8 g (145.4 mmol) of sodium triacetoxyborohydride. After the resulting mixture was shaken at rt for 65 h under argon gas, the resin was washed with CH2Cl2/methanol (1:1, 3 x 400 mL), DMF (3 x 400 mL), CH2C12 (1 x 400 mL) and methanol (2 x 400 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. Elemental analysis N: 4.27, S: 5.25. To a mixture of 10 g (7.914 mmol, 0.7914 mmol/g) of the above resin in 165 mL of anhydrous l-methyl-2-pyrrolidinone was added 13.985 g (39.57 mmol) of Fmoc-Leu-OH and 1.077 g (7.914 mmol) of l-hydroxy-7-azabenzotriazole, followed by addition of 7.490 mL (47.48 mmol) of 1,3-diisopropylcarbodiimide. After the resulting mixture was shaken at rt for 44 h, the resin was washed with l-methyl-2-pyrrolidinone (3 x 150 mL), dichloroethane/methanol (1:1, 3 x 150 mL) and methanol (3 x 150 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated in vacuo: MS (ESI) 621 [M+H]+.
The above resin (7.914 mmol) was treated with 175 mL of 20% piperidine in anhydrous l-methyl-2-pyrrolidinone solution. After the mixture was shaken at rt for 15 min, the solution was drained and another 175 mL of 20% piperidine in anhydrous 1- methyl-2-pyrrolidinone solution was added. The mixture was shaken at rt for another 15 min. The solution was drained and the resin was washed with l-methyl-2-pyrrolidinone (3 x 175 mL), CH2Cl2/MeOH (1:1, 3 x 175 mL) and CH2C12 (3 x 175 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated in vacuo: MS (ESI) 399 [M+H]+.
To a mixture of 200 mg (0.1453 mmol, 0.7264 mmol/g) of the above dry resin in 5 mL of anhydrous l-methyl-2-pyrrolidinone was added 129.5 mg (0J265 mmol) of benzo[b]thiophene-2-carboxylic acid and 19.8 mg (0.1453 mmol) of l-hydroxy-7- azabenzotriazole, followed by addition of 0.137 mL (0.8718 mmol) of 1,3- diisopropylcarbodiimide. After the resulting mixture was shaken at rt for 48 h, the resin was washed with l-methyl-2-pyrrolidinone (3 x 10 mL), CH2Cl2/MeOH (1:1, 3 x 10 mL) and
CH2C12 (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated in vacuo: MS (ESI) 559 [M+H]+.
To a mixture of 0.1453 mmol of the above dry resin in 6 mL of l-methyl-2- pyrrolidinone was added 200.8 mg (1.453 mmol) of K2C03 and 0.0746 mL (0.7265 mmol) of PhSH. After the resulting mixture was shaken at it for 20 h, the resin was washed with methanol (1 x 10 mL), H20 (3 x 10 mL), methanol (1 x 10 mL), l-methyl-2-pyrrolidinone (1 x 10 mL), CH2Cl2/methanol (1:1, 3 x 10 mL) and methanol (3 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at it. The resulting solution was concentrated in vacuo: MS (ESI) 747 [2M+H]+, 374 [M+H]+.
To a mixture of 0.1453 mmol of the above dry resin in anhydrous dichloroethane/1- methyl-2-pyrrolidinone solution (1:1, 7.5 mL) was added 0.2264 mL (2.799 mmol) of pyridine followed by the slow addition of 0.5393 g (2.799 mmol) of 4- hydroxybenzenesulfonyl chloride. After the resulting mixture was shaken at rt for 96 h, the resin was washed with l-methyl-2-pyrrolidinone (3 x 10 mL), dichloroethane/methanol (1:1,
3 x 10 mL), dichloroethane (3 x lOmL), methanol (1 x 10 mL), and dichloroethane (2 x lOmL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. To a mixture of the dry resin in anhydrous tetrahydrofuran (9.38 mL) was added 0.4713 g (3.674 mmol) of potassium trimethyl silanolate. After the reaction mixture was shaken for 23 h, the resin was washed with tetrahydrofuran (3 x lOmL), l-methyl-2-pyrrolidinone (2 x lOmL), tetrahydrofuran (3 x lOmL), dichloroethane/methanol (5 x 10 mL), and dichloroethane (3 x 10 mL). An analytical amount of resin was cleaved with 50% trifluoroacetic acid in dichloroethane for 2 h at rt. The resulting solution was concentrated in vacuo: MS (ESI)
530 [M+H]+. To a mixture of 200 mg of the above dry resin in 8.75 mL of anhydrous tetrahydrofuran was added 443 mg (2.199 mmol) of 4-Hydroxypiperidine-l-carboxylic acid tert-butyl ester and 577 mg (2.199 mmol) of triphenylphosphine. After the mixture was cooled to -70 °C, 433 μL (2.199 mmol) of diisopropyl azodicarboxylate was added to the cold mixture. The resulting mixture was kept at -70 °C for 30 min while shaking. The mixture was then allowed to warm to 0 °C over 1 h and shaken at rt for 19 h. The resin was washed with tetrahydrofuran (3 x 10 mL), CH2Cl2/methanol (1:1, 10 x 10 mL). The resulting resin was dried in vacuum oven at 35 °C for 24 h. The dry resin was treated with
4 mL of 50% trifluoroacetic acid in dichloroethane at rt for 2h. After the cleavage solution was collected, the resin was treated with another 4 mL of 50% trifluoroacetic acid in dichloroethane at rt for lOmin. The combined cleavage solutions were concentrated in vacuo. The residue was purified using a Gilson semi-preparative HPLC system with a YMC ODS-A (C-18) column 50 mm by 20 mm ID, eluting with 10% B to 90% B in 3.2 min, hold for 1 min where A = H2O (0.1% trifluoroacetic acid) and B = CH3CN (0.1% trifluoroacetic acid) pumped at 25 mL/min, to produce benzo[b]thiophene-2-carboxylic acid ((S)-3-methyl-l-{ l-[4-(piρeridin-4-yloxy)-benzenesulfonyl]-piperidin-4-ylcarbamoyl}- butyl)-amide as a mono-trifluoroacetic acid salt (white powder, 23.0 mg, 28% over 11 steps): MS (ESI) 642 [M+H]+.
Compounds derived from Scheme 1:
EXAMPLE 11 Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
Tablets/Ingredients Per Tablet 1. Active ingredient 40 mg (Cpd of Form. I) 2.Corn Starch 20 mg 3.Alginic acid 20 mg 4.Sodium Alginate 20 mg 5.Mg stearate 1.3 mg
2.3 mg
Procedure for tablets:
Step 1: Blend ingredients No. 1, No. 2, No. 3 and No. 4 in a suitable mixer/blender. ■ Step 2: Add sufficient water portion-wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
Step 3: The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
Step 4: The wet granules are then dried in an oven at 140°F (60°C) until dry.
Step 5: The dry granules are lubricated with ingredient No. 5. Step 6: The lubricated granules are compressed on a suitable tablet press.
Inhalant Formulation
A compound of Formula I, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use. Parenteral Formulation
A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.

Claims

What is claimed is:
1. A compound of Formula (I):
Formula (I) wherein:
R is Cι_(5 alkyl, benzyl, or (CH2)n- (0)NH2; wherein the benzyl may be unsubstituted or substituted by one or two Cι_g alkyl, halogen, Cι_g alkoxy, or methylenedioxy groups; R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, C1.3 alkyl, C _3 alkoxy, or methylenedioxy groups;
X and X2 are independently hydrogen, halogen, C _3 alkyl, C _3 alkoxy, nitro, CF3, or
CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 wherein m is 1 or 2; Ri is isobutyl; R2 is benzothiopheneyl; X is hydrogen, 3-Bromo, or 3-Chloro; and X2 is hydrogen or 5-Chloro.
3. A compound of claim 1 chosen from the group consisting of:
Benzo[&]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-chloro-4-(piperidin-4-yloxy)- benzenesulf onyl] -piperazin- 1 -yl } -ethylcarbamoyl)-3-methyl-butyl] - ;
Benzo[έ]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-bromo-4-(piperidin-4-yloxy)- benzenesulfonylj-piperazin- 1 -yl } -ethylcarbamoyl)-3-methyl-butyl]-amide; Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-chloro-4-((S)-pyrrolidin-3-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide;
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3-bromo-4-((S)-pyrrolidin-3-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-3-methyl-butyl]-amide;
Benzo[b]thiophene-2-carboxylic acid [(S)-3-methyl-l~(2-{4-[4-(piperidin-4-yloxy)- benzenesulfonyl]-piperazin-l-yl}-ethylcarbamoyl)-butyl]-amide; and
Benzo[b]thiophene-2-carboxylic acid [(S)-l-(2-{4-[3,5-dichloro-4-(piperidin-4-yloxy)- benzenesulf onyl] -piperazin- 1 -yl } -ethylcarbamoyl)-3 -methyl-butyl] -amide .
4. A pharmaceutical composition comprising a compound of formula (I) of claim 1 and a pharmaceutically acceptable carrier or excipient.
5. A method of treating conditions associated with Urotensin-II imbalance by antagonizing the Urotensin-II receptor which comprises administering to a patient in need thereof, a compound of Formula I of claim 1.
6. A method according to Claim 5 wherein the disease is congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrythmias, essential hypertension, pulmonary hypertension, COPD, restenosis, asthma, neurogenic inflammation metabolic vasculopathies, addiction, schizophrenia, cognitive disorders/Alzheimers disease, impulsivity, anxiety, stress, depression, neuromuscular function, or diabetes.
EP02757820A 2001-03-29 2002-03-28 Pyrrolidine sulfonamides Withdrawn EP1381365A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27959201P 2001-03-29 2001-03-29
US27961001P 2001-03-29 2001-03-29
US279610P 2001-03-29
US279592P 2001-03-29
PCT/US2002/009445 WO2002078707A1 (en) 2001-03-29 2002-03-28 Pyrrolidine sulfonamides

Publications (2)

Publication Number Publication Date
EP1381365A1 true EP1381365A1 (en) 2004-01-21
EP1381365A4 EP1381365A4 (en) 2005-03-23

Family

ID=26959764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02757820A Withdrawn EP1381365A4 (en) 2001-03-29 2002-03-28 Pyrrolidine sulfonamides

Country Status (3)

Country Link
EP (1) EP1381365A4 (en)
JP (1) JP2004524355A (en)
WO (1) WO2002078707A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1499607T1 (en) 2001-12-04 2006-06-30 Actelion Pharmaceuticals Ltd 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
WO2005030209A1 (en) 2003-09-26 2005-04-07 Actelion Pharmaceuticals Ltd Pyridine derivatives and use thereof as urotensin ii antagonists
AU2005293196B2 (en) 2004-10-12 2012-03-22 Actelion Pharmaceuticals Ltd 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO02078707A1 *

Also Published As

Publication number Publication date
JP2004524355A (en) 2004-08-12
EP1381365A4 (en) 2005-03-23
WO2002078707A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
US20040198979A1 (en) Sulfonamides
EP1385840B1 (en) Sulfonamides
US20040152692A1 (en) Pyrrolidine sulfonamides
US6544992B1 (en) Urotensin-II receptor antagonists
US20040152893A1 (en) Sulfonamides
US7019008B2 (en) Pyrrolidine sulfonamides
WO2001045694A1 (en) Urotensin-ii receptor antagonists
EP1246619B1 (en) Urotensin-ii receptor antagonists
US20040082566A1 (en) Pyrrolidine sulfonamides
EP1385841A1 (en) Sulfonamides
US20040142923A1 (en) Pyrrolidine sulfonamides
EP1385495A2 (en) Sulfonamides
EP1381365A1 (en) Pyrrolidine sulfonamides
EP1385830A1 (en) Sulfonamides
WO2004043369A2 (en) Sulfonamides
WO2004043948A1 (en) Sulfonamides
US20040142948A1 (en) Sulfonamides
US20040152895A1 (en) Sulfonamides
AU2002303678A1 (en) Sulfonamides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050209

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 409/12 B

Ipc: 7C 07D 409/14 B

Ipc: 7A 61K 31/496 A

17Q First examination report despatched

Effective date: 20070206

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/30 20060101ALI20070731BHEP

Ipc: A61P 25/28 20060101ALI20070731BHEP

Ipc: A61P 25/24 20060101ALI20070731BHEP

Ipc: A61P 25/18 20060101ALI20070731BHEP

Ipc: A61P 11/06 20060101ALI20070731BHEP

Ipc: A61P 9/12 20060101ALI20070731BHEP

Ipc: A61P 9/10 20060101ALI20070731BHEP

Ipc: A61P 9/04 20060101ALI20070731BHEP

Ipc: A61P 9/00 20060101ALI20070731BHEP

Ipc: C07D 409/12 20060101ALI20070731BHEP

Ipc: C07D 409/14 20060101ALI20070731BHEP

Ipc: A61K 31/496 20060101AFI20070731BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071228